CODX logo

Co-Diagnostics, Inc.

CODX
Healthcare|Biotechnology|US
$0.26
-0.01 (-3.86%)
DCF Value
$7.41
Tangible Book / Share
$1.27
Cash / Share
$0.85
Financing Filings (last 12 months)
6
Shelf registrations / offering prospectuses — latest Nov 4, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (62)

Dec 2026
Est. completion
Gastric Antral Vascular Ectasia
Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias
NCT06306963n=30
Dec 2026
Est. completion
P4Prostate Cancer
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
NCT05722925n=50
Dec 2026
Est. completion
Heart Failure
Biomarkers to Classify Heart Failure
NCT02347722n=511
Dec 2026
Est. completion
Polycystic Ovarian Syndrome (PCOS)
Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study
NCT06642831n=380
Dec 2026
Est. completion
Early P1Glioma
18F-Fluciclovine PET-MRI in High-grade Glioma
NCT05553041n=30
Dec 2026
Est. completion
Non-alcoholic Fatty Liver
Identification of Liver Fibrosis Biomarkers
NCT06819917n=575
Dec 2026
Est. completion
Prostate Cancer
Molecular Studies and Clinical Correlations in Human Prostatic Disease
NCT00578240n=5,290
Dec 2026
Est. completion
P1P2Pneumocystis Pneumonia
CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
NCT06892951n=100
Dec 2026
Est. completion
P2Intermediate Risk Prostate Cancer
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
NCT07393867n=23
Dec 2026
Est. completion
Sepsis, Septic Shock
Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study
NCT07425587n=450
Dec 2026
Est. completion
NARespiratory Tract Infections
An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.
NCT06070688n=100
Dec 2026
Est. completion
P2P3Lung Cancer
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
NCT04093167n=53
Dec 2026
Est. completion
Colorectal Cancer
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance
NCT07310446n=6,500
Dec 2026
Est. completion
Sepsis, Septic Shock
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
NCT06654895n=700
Feb 2027
Est. completion
NALower Respiratory Tract Infection
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
NCT05762302n=1,316
Feb 2027
Est. completion
Ovarian Neoplasms
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass
NCT06566716n=1,000
Mar 2027
Est. completion
P1Brain Metastases, Adult
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
NCT04689048n=20
Mar 2027
Est. completion
NACognition
Trial of Pistachio Consumption in Older Adults
NCT06992544n=97
Mar 2027
Est. completion
Cardiovascular Diseases
Phase I Human Analytics (HALO) Study
NCT05423860n=2,000
Mar 2027
Est. completion
Acute Respiratory Infections (ARIs)
FebriDx® Pediatric Validation Study
NCT07211997n=800

Awaiting Results (11)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
NCT03524430
Sep 2026
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
NCT05579236
Jun 2026
NA
Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19
NCT05220163
Jan 2026
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
NCT06652100
Nov 2025
P2
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
NCT05833438
Sep 2025
P2P3
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
NCT04337450
May 2025
NA
ABC-Scores for Reduction of Stroke and Mortality in Atrial Fibrillation - The ABC-AF Study
NCT03753490
May 2025
P3
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NCT05678322
Feb 2025
Point of Care Evaluation of High-sensitivity Cardiac Troponin
NCT05665127
Nov 2022
NA
Predictive Monitoring - IMPact in Acute Care Cardiology Trial
NCT04359641

Recent Press Releases

Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast
Nov 5, 2026 · PRNewsWire
Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch
Nov 5, 2026 · PRNewsWire
Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast
Oct 29, 2026 · PRNewsWire
Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test
Oct 29, 2026 · PRNewsWire
Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India
Oct 27, 2026 · PRNewsWire
Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
Oct 20, 2026 · PRNewsWire
Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
Oct 15, 2026 · PRNewsWire
Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
Oct 8, 2026 · PRNewsWire
Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
Oct 7, 2026 · PRNewsWire
Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
Oct 6, 2026 · PRNewsWire

SEC Filings (70)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 2026S-3Shelf registrationDocumentIndex
Oct 26, 2026DEF 14AProxy / shareholder voteDocumentIndex
Oct 16, 2026PRE 14AProxy / shareholder voteDocumentIndex
Oct 15, 20268-KMaterial eventDocumentIndex
Oct 15, 20268-K/AMaterial eventDocumentIndex
Oct 13, 20268-KMaterial eventDocumentIndex
Oct 5, 20268-KMaterial eventDocumentIndex
Sep 25, 20268-KMaterial eventDocumentIndex
Sep 21, 2026PRE 14AProxy / shareholder voteDocumentIndex
Sep 16, 20268-KMaterial eventDocumentIndex
Sep 16, 20268-KMaterial eventDocumentIndex
Sep 15, 20268-KMaterial eventDocumentIndex
Sep 4, 20268-KMaterial eventDocumentIndex
Sep 4, 2026DEFA14AProxy / shareholder voteDocumentIndex
Sep 4, 20268-KMaterial eventDocumentIndex
Sep 1, 2026EFFECTDocumentIndex
Aug 24, 2026S-3Shelf registrationDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 10, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 31, 20268-KMaterial eventDocumentIndex
Jul 27, 20268-KMaterial eventDocumentIndex
Jul 27, 2026424B5Offering prospectusDocumentIndex
Jul 21, 2026DEF 14AProxy / shareholder voteDocumentIndex
Jul 10, 2026PRE 14AProxy / shareholder voteDocumentIndex
May 29, 2026EFFECTDocumentIndex
May 28, 2026S-3Shelf registrationDocumentIndex
May 21, 20268-KMaterial eventDocumentIndex
May 15, 2026EFFECTDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 12, 2026S-3Shelf registrationDocumentIndex
Mar 31, 202610-KAnnual reportDocumentIndex
Mar 31, 20268-KMaterial eventDocumentIndex
Mar 10, 20268-KMaterial eventDocumentIndex
Feb 11, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 21, 2026S-8Employee stock planDocumentIndex
Jan 13, 20268-KMaterial eventDocumentIndex
Dec 30, 20258-KMaterial eventDocumentIndex